Bilateral Pharmacokinetic Interaction between Cyclosporine A and Atorvastatin in Renal Transplant Recipients

American Journal of Transplantation

Volumn 1, Issue 4, 2001, Pages 382-386

  Åsberg, Anders ^a   Hartmann, Anders ^a   Fjeldså, Ellen ^a   Bergan, Stein ^a   Holdaas, Hallvard ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Atorvastatin; Cyclosporine A; Interaction; Lipids; Pharmacokinetics; Renal transplantation

Indexed keywords

ATORVASTATIN; BASILIXIMAB; CYCLOSPORIN; DIAGNOSTIC AGENT; HEPTANOIC ACID DERIVATIVE; HYBRID PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PREDNISOLONE; PYRROLE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG INTERACTION; FEMALE; HUMAN; IMMUNOLOGY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED;

ADULT; AGED; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; CYCLOSPORINE; DRUG INTERACTIONS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PREDNISOLONE; PYRROLES; RECOMBINANT FUSION PROTEINS;

EID: 0035502455     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2001.10415.x     Document Type: Article

References (29)

1. Wierzbicki AS. The role of lipid lowering in transplantation. Int J Clin Pract 1999; 53: 54-59.
2. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57: 307-313.
3. Mück W, Mai I, Fritsche L et al. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ther 1999; 65: 251-261.
4. Olbricht C, Wanner C, Eisenhauer T et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 1997; 62: 311-321.
5. Goldberg R, Roth D. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation 1996; 62: 1559-1564.
6. Campana C, Iacona I, Regazzi MB et al. Efficacy and pharmacokinetics of simvastatin in heart transplant recipients. Ann Pharmacother 1995; 29: 235-239.
7. Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther 1998; 80: 1-34.
8. Prueksaritanont T, Gorham LM, Ma B et al. In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 1997; 25: 1191-1199.
9. Malinowski JM. Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor. Am J Health Syst Pharm 1998; 55: 2253-2267(quiz: 2302-2253).
10. Mück W. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions. Drugs 1998; 56: 15-23.
11. Jacobsen W, Kirchner G, Hallensleben K et al. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos 1999; 27: 173-179.
12. Fischer V, Johanson L, Heitz F et al. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos 1999; 27: 410-416.
13. Xu F, Wu ZH, Zhang ZY, Zou HQ. Delay of metabolism rate of ciclosporin by simvastatin in 7 Chinese healthy men. Chung Kuo Yao Li Hsueh Pao 1998; 19: 443-444.
14. Cheung AK, DeVault GA Jr, Gregory MC. A prospective study on treatment of hypercholesterolemia with lovastatin in renal transplant patients receiving cyclosporine. J Am Soc Nephrol 1993; 3: 1884-1891.
15. Kuo PC, Kirshenbaum JM, Gordon J et al. Lovastatin therapy for hypercholesterolemia in cardiac transplant recipients. Am J Cardiol 1989; 64: 631-635.
16. Renders L, Mayer-Kadner I, Koch C et al. Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients. Nephrol Dial Transplant 2001; 16: 141-146.
17. Gullestad L, Nordal KP, Forfang K et al. Post-transplant hyperlipidaemia: low-dose lovastatin lowers atherogenic lipids without plasma accumulation of lovastatin. J Intern Med 1997; 242: 483-490.
18. Gullestad L, Nordal KP, Berg KJ, Cheng H, Schwartz MS, Simonsen S. Interaction between lovastatin and cyclosporine A after heart and kidney transplantation. Transplant Proc 1999; 31: 2163-2165.
19. Kobashigawa JA, Moriguchi JD, Sabad A et al. Cyclosporine and pravastatin pharmacokinetics in cardiac transplant recipients. J Heart Lung Transplant 1997; 16: 84.
20. Amadottir M, Eriksson LO, Thysell H, Karkas JD. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 1993; 65: 410-413.
21. Regazzi MB, Iacona I, Campana C et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 1993; 25: 2732-2734.
22. Stern RH, Yang BB, Horton M, Moore S, Abel RB, Olson SC. Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin. J Clin Pharmacol 1997; 37: 816-819.
23. Bergan S, Rugstad HE, Stokke O, Bentdal O, Frøysaker T, Bergan A. Cyclosporine A monitoring in patients with renal, cardiac, and liver transplants: a comparison between fluorescence polarization immunoassay and two different RIA methods. Scand J Clin Lab Invest 1993; 53: 471-477.
24. Shum YY, Huang N, Walter G et al. Development validation, and interlaboratory comparison of an HMG-CoA reductase inhibition assay for quantitation of atorvastatin in plasma matrices. Ther Drug Monit 1998; 20: 41-49.
25. Smith PF, Eydelloth RS, Grossman SJ et al. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. J Pharmacol Exp Ther 1991; 257: 1225-1235.
26. Wu X, Whitfield LR, Stewart BH. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm Res 2000; 17: 209-215.
27. Boyd RA, Stern RH, Stewart BH et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-grycoprotein-mediated secretion. J Clin Pharmacol 2000; 40: 91-98.
28. Hsiang B, Zhu Y, Wang Z et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 1999; 274: 37161-37168.
29. Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 1997; 27: 201-214.